Qumis | $2,200,000 | (Jan 22, 2025)
Zynap | $5,937,902 | (Jan 22, 2025)
Belfry | $12,000,000 | (Jan 22, 2025)
Certified by Founder
Lodge
Ancilia Biosciences
start up
United States
- New York, New York
- 29/08/2024
- Unknown
- $4,200,000
Ancilia is harnessing the natural power of CRISPR to develop a new class of bacterial therapies and products for a range of applications.
- Industry Biotechnology
- Website https://www.anciliabio.com/
- LinkedIn https://www.linkedin.com/company/ancilia/
Gravity(US) | $13,000,000 | (Jan 22, 2025)
LeapXpert | $20,000,000 | (Jan 22, 2025)
BPR Hub | $2,600,000 | (Jan 22, 2025)
NovoLINC | Undisclosed Amount | (Jan 22, 2025)
IntusCare | $11,500,000 | (Jan 21, 2025)
ecoplanet | $16,571,680 | (Jan 21, 2025)
Sereact | $25,894,660 | (Jan 21, 2025)
Fundment | $55,157,175 | (Jan 21, 2025)
Men In Blazers Media Network | $150,000,000 | (Jan 21, 2025)